Soleno Therapeutics, Inc focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is diazoxide choline controlled-release, a tablet that is in Phase III clinical trial for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc and changed its name to Soleno Therapeutics, Inc in May 2017.
Read More…
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Phone650-213-8444
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.45 million
Profitability
Miscellaneous
Employees9
Next Earnings Date11/21/2019 (Estimated)
OptionableNot Optionable
Soleno Therapeutics (NASDAQ:SLNO) Frequently Asked Questions
What is Soleno Therapeutics' stock symbol?
Soleno Therapeutics trades on the NASDAQ under the ticker symbol "SLNO."
When did Soleno Therapeutics' stock split? How did Soleno Therapeutics' stock split work?
Soleno Therapeutics's stock reverse split on the morning of Friday, October 6th 2017. The 1-5 reverse split was announced on Thursday, October 5th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 5th 2017. An investor that had 100 shares of Soleno Therapeutics stock prior to the reverse split would have 20 shares after the split.
How were Soleno Therapeutics' earnings last quarter?
Soleno Therapeutics Inc (NASDAQ:SLNO) posted its quarterly earnings results on Wednesday, August, 7th. The company reported ($0.31) EPS for the quarter, missing the Zacks' consensus estimate of ($0.18) by $0.14. View Soleno Therapeutics' Earnings History.
When is Soleno Therapeutics' next earnings date?
What price target have analysts set for SLNO?
2 brokerages have issued twelve-month price targets for Soleno Therapeutics' stock. Their forecasts range from $5.00 to $10.00. On average, they anticipate Soleno Therapeutics' share price to reach $7.50 in the next year. This suggests a possible upside of 298.9% from the stock's current price. View Analyst Price Targets for Soleno Therapeutics.
What is the consensus analysts' recommendation for Soleno Therapeutics?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Soleno Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Soleno Therapeutics.
Has Soleno Therapeutics been receiving favorable news coverage?
Press coverage about SLNO stock has been trending positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Soleno Therapeutics earned a media sentiment score of 2.5 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the stock's share price in the next few days. View News Stories for Soleno Therapeutics.
Who are some of Soleno Therapeutics' key competitors?
Some companies that are related to Soleno Therapeutics include Stereotaxis (STXS), BioSig Technologies (BSGM), Rockwell Medical (RMTI), Fonar (FONR), Second Sight Medical Products (EYES), Edap Tms (EDAP), Fc Global Realty (FCRE), electroCore (ECOR), Helius Medical Technologies (HSDT), IRIDEX (IRIX), Precision Optics (PEYE), ENDRA Life Sciences (NDRA), Digirad (DRAD), Nexeon Medsystems (NXNN) and CHF Solutions (CHFS).
What other stocks do shareholders of Soleno Therapeutics own?
Who are Soleno Therapeutics' key executives?
Soleno Therapeutics' management team includes the folowing people:
- Dr. Anish Bhatnagar, Pres, CEO & Director (Age 49)
- Mr. Anthony Wondka, Sr. VP of R&D (Age 57)
- Mr. David D. O'Toole, Consultant (Age 60)
- Mr. Jonathan R. Wolter, CFO & Principal Accounting Officer (Age 69)
- Dr. Neil M. Cowen Ph.D., MBA, Sr. VP of Drug Devel.
Who are Soleno Therapeutics' major shareholders?
Soleno Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Vivo Capital LLC (13.43%), Trellus Management Company LLC (0.84%), Vanguard Group Inc. (0.77%), BlackRock Inc. (0.23%), Bank of New York Mellon Corp (0.06%) and Lindbrook Capital LLC (0.03%). Company insiders that own Soleno Therapeutics stock include Bioasia Mangement Llc, Edgar Engleman, Jack W Schuler, Larry N Feinberg and Technology Partners Fund Vii L. View Institutional Ownership Trends for Soleno Therapeutics.
Which major investors are selling Soleno Therapeutics stock?
SLNO stock was sold by a variety of institutional investors in the last quarter, including Vivo Capital LLC. Company insiders that have sold Soleno Therapeutics company stock in the last year include Bioasia Mangement Llc and Technology Partners Fund Vii L. View Insider Buying and Selling for Soleno Therapeutics.
Which major investors are buying Soleno Therapeutics stock?
SLNO stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Trellus Management Company LLC, Bank of New York Mellon Corp and Lindbrook Capital LLC. Company insiders that have bought Soleno Therapeutics stock in the last two years include Edgar Engleman, Jack W Schuler and Larry N Feinberg. View Insider Buying and Selling for Soleno Therapeutics.
How do I buy shares of Soleno Therapeutics?
Shares of SLNO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Soleno Therapeutics' stock price today?
One share of SLNO stock can currently be purchased for approximately $1.88.
How big of a company is Soleno Therapeutics?
Soleno Therapeutics has a market capitalization of $59.77 million and generates $1.45 million in revenue each year. The company earns $-13,340,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. Soleno Therapeutics employs 9 workers across the globe.View Additional Information About Soleno Therapeutics.
What is Soleno Therapeutics' official website?
How can I contact Soleno Therapeutics?
Soleno Therapeutics' mailing address is 1235 RADIO ROAD SUITE 110, REDWOOD CITY CA, 94065. The company can be reached via phone at 650-213-8444 or via email at [email protected]
MarketBeat Community Rating for Soleno Therapeutics (NASDAQ SLNO)
MarketBeat's community ratings are surveys of what our community members think about Soleno Therapeutics and other stocks. Vote "Outperform" if you believe SLNO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLNO will underperform the S&P 500 over the long term. You may vote once every thirty days.
